I-mab Share Price Today
(NASDAQ: IMAB)

Name: I-mab Share Price Today (NASDAQ: IMAB) - I-mab Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

I-mab share price is $0.9 & ₹78.27 as on 6 Mar 2025, 2.30 'hrs' IST

$0.9

Market is closed - opens 8 PM, 06 Mar 2025

View live I-mab share price in Dollar and Rupees. Guide to invest in I-mab stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in I-mab, along with analyst recommendations, forecasts, and comprehensive financials.

I-mab share price movements

Today's Low: $0.81
Today's High: $0.90
$0.90
9.78%
Downside
Day's Volatility :9.9%
Upside
0.13%
52 Weeks Low: $0.84
52 Weeks High: $2.00
$0.90
6.56%
Downside
52 Weeks Volatility :57.95%
Upside
55.0%

I-mab (IMAB) Returns

Period	I-mab	Sector (Health Care)	Index (Russel 2000)
3 Months	-14.19%	2.1%	0.0%
6 Months	-14.19%	-4.1%	0.0%
1 Year	-47.92%	2.2%	0.0%
3 Years	-95.69%	11.8%	-11.6%

I-mab (IMAB) Key Statistics

in dollars & INR

Previous Close	$0.901
Open	$0.81
Today's High	$0.9012
Today's Low	$0.812
Market Capitalization	$85.7M
Today's Volume	$26.0K
52 Week High	$2.0
52 Week Low	$0.812
Revenue TTM	$3.5M
EBITDA	$-169.3M
Earnings Per Share (EPS)	$-2.16
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-71.72%

How to invest in I-mab Stock (IMAB) from India?

It is very easy for Indian residents to invest directly in I-mab from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the I-mab stock in both Indian Rupees (INR) and US Dollars (USD). Search for I-mab or IMAB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of I-mab or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of I-mab shares which would translate to 0.966 fractional shares of I-mab as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like I-mab, in just a few clicks!

Returns in I-mab (IMAB) for Indian investors in Rupees

The I-mab stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

I-mab investment value today

Current value as on today

₹56,986

Returns

₹43,014

(-43.01%)

Returns from I-mab Stock

₹47,977 (-47.98%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards I-mab (IMAB)

13%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for I-mab Stock from India on INDmoney has increased by 13% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in I-mab

Hillhouse Capital Advisors, Ltd.
7.34%
Morgan Stanley - Brokerage Accounts
4.35%
SG Americas Securities, LLC
0.58%
Two Sigma Advisers, LLC
0.53%
Two Sigma Investments LLC
0.41%
EDBI Pte Ltd
0.27%

Analyst Recommendation on I-mab

Buy

90%Buy

9%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for I-mab(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on I-mab Stock (IMAB)

What analysts predicted

Upside of 650.0%

Target:

$6.75

Current:

$0.90

Insights on I-mab Stock (Ticker Symbol: IMAB)

Price Movement
In the last 3 years, IMAB stock has moved down by -95.7%
Increasing Revenue
Revenue is up for the last 2 quarters, 3.27M → 3.99M (in $), with an average increase of 18.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 25.12M → -20.49M (in $), with an average decrease of 181.6% per quarter
IMAB vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 109.0%
IMAB vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 143.4%
Price to Sales
ForIMAB every $1 of sales, investors are willing to pay $21.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

I-mab Technicals Summary

Sell

Neutral

Buy

I-mab is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

I-mab (IMAB) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
I-mab	-6.15%	-14.19%	-47.92%	-95.69%	-98.87%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
I-mab	NA	NA	NA	0.0	-0.72	-0.29	NA	2.91
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
I-mab	Buy	$85.7M	-98.87%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About I-mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Organization	I-mab
Employees	220
CEO	Dr. Xi-Yong Fu M.B.A., Ph.D.
Industry	Health Technology

Management People of I-mab

Name	Title
Dr. Xi-Yong Fu M.B.A., Ph.D.	CEO & Director
Mr. Skelton Joseph	Chief Financial Officer
Mr. Tyler Ehler	Senior Director of Investor Relations
Dr. Fernando J. Salle´s Ph.D.	Senior VP and Head of U.S. & EU Business Development
Dr. Louie Naumovski M.D., Ph.D.	Interim Chief Medical Officer
Dr. Phillip Dennis M.D., Ph.D.	Chief Medical Officer

Important FAQs about investing in IMAB Stock from India :

What is I-mab share price today?

I-mab share price today stands at $0.90, Open: $0.81 ; Previous Close: $0.90 ; High: $0.90 ; Low: $0.81 ; 52 Week High: $2.00 ; 52 Week Low: $0.84.

The stock opens at $0.81, after a previous close of $0.90. The stock reached a daily high of $0.90 and a low of $0.81, with a 52-week high of $2.00 and a 52-week low of $0.84.

Can Indians buy I-mab shares?

Yes, Indians can invest in the I-mab (IMAB) from India.

With INDmoney, you can buy I-mab at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy I-mab at zero transaction cost.

How can I buy I-mab shares from India?

It is very easy to buy I-mab from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of I-mab (IMAB) be purchased?

Yes, you can buy fractional shares of I-mab with INDmoney app.

What are the documents required to start investing in I-mab stocks?

To start investing in I-mab, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.